GlassScriptPhysician profile
Catherine B Anderson
NPI 1477868867
$5,625.50
in general payments reported to CMS, 2019-2025
55 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 85% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $936 · 2023: $2,780 · 2024: $693 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,399 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,398.67 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $627.70 | 2022-2025 | Enhertu, Lynparza, Calquence |
| Novartis Pharmaceuticals Corporation | $502.34 | 2022-2025 | |
| Janssen Biotech, INC. | $464.67 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Puma Biotechnology, INC. | $436.66 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $284.64 | 2023-2024 | Keytruda, Lynparza |
| Karyopharm Therapeutics INC. | $206.67 | 2022-2024 | Xpovio |
| Eisai INC. | $202.13 | 2022-2025 | |
| Pfizer INC. | $196.55 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $184.41 | 2022-2025 | Opdivo, Opdualag |
| Amgen INC. | $170.40 | 2021-2023 | Lumakras, Blincyto, Kyprolis |
| Incyte Corporation | $156.10 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Abbvie INC. | $142.38 | 2022-2024 | |
| Blueprint Medicines Corporation | $141.27 | 2023 | Ayvakit |
| Kite Pharma, INC. | $123.26 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $118.86 | 2023-2025 | Onivyde, Somatuline Depot, Tazverik |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.